Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bactecal GE
- Development stage
- Unknown
- Lead developer
- Astel Medica
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bactecal GE is a multi-strain probiotic and postbiotic dietary supplement developed by Astel Medica, a company based in Belgium and Luxembourg. It is specifically formulated to support digestive health and optimize intestinal transit, particularly in cases of soft stools or acute gastroenteritis. Each oral capsule contains 18 billion live bacteria from five specific strains: *Lactobacillus rhamnosus*, *Lactobacillus acidophilus*, *Bifidobacterium infantis*, *Bifidobacterium lactis*, and *Streptococcus thermophilus*. The formulation is further enhanced with the botanical ingredient *Terminalia chebula* (myrobalan), the prebiotic fructo-oligosaccharides (FOS), and vitamins A and D3. Clinical studies have indicated its efficacy in reducing the duration of diarrhea when used as an adjunct to oral rehydration therapy. The product is lactose-free, gluten-free, and suitable for use during pregnancy and breastfeeding.
- Brand names
- Bactecal GE
- Other names
- Bactecal® GE
02
Targets
RAR (Retinoic acid receptor)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Bactecal GE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bactecal GE.